CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 151-153
DOI: 10.4103/0971-5851.123707
EDITORIAL COMMENTARY

Will kinase domain mutations dictate the terms…

M B Agarwal
Department of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India
,
Shyam A Rathi
Department of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India
› Author Affiliations


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-92.
  • 2 Srivastava S, Dutt S. Imatinib mesylate resistance and mutations: An Indian Experience. Indian J Med Paediatr Oncol 2013;34:213-20.
  • 3 Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29.
  • 4 Kantarjian HM, Larson RA, Guilhot F, O′Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-60.
  • 5 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9.
  • 6 Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6.
  • 7 Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: What have we learned? Blood 2011;117:755-63.
  • 8 Rajappa S, Mallavarapu KM, Gundeti S, Paul TR, Jacob RT, Digumarti R. Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Indian J Med Paediatr Oncol 2013;34:221-3.